Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shot shows promise for major weight loss

NCT ID NCT06388187

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goals were to see how much weight they lost and how many achieved at least a 5% weight reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Addenbrooke's Hospital_Cambridge

    Cambridge, CB2 0QQ, United Kingdom

  • AmBeNet GmbH

    Leipzig, 04107, Germany

  • Aurora FDRC Inc.

    Costa Mesa, California, 92627, United States

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502, United States

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

    Saint-Herblain, 44800, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, 31059, France

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida, 33324, United States

  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann

    Witten, 58455, Germany

  • Hospices Civils de Lyon-Hopital Lyon Sud

    Pierre-Bénite, 69310, France

  • Hospices Civils de Lyon-Hopital Lyon Sud-1

    Pierre-Bénite, 69310, France

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

    Münster, 48145, Germany

  • Joint Clinical Research Facility - Swansea

    Swansea, SA2 8PP, United Kingdom

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Southmead Hospital

    Bristol, BS10 5NB, United Kingdom

  • Staploe Medical Centre

    Soham, CB7 5JD, United Kingdom

  • The Health Centre

    Bradford-on-Avon, BA15 1DQ, United Kingdom

  • University Hospital Coventry - WISDEM Centre

    Coventry, CV2 2DX, United Kingdom

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Wendisch - Dahl Hamburg - DZHW

    Hamburg, 22607, Germany

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.